Errata - English

PDF CSV October 5, 2022 through October 5, 2024 All Errata for USP–NF How to use
Enter the title of the monograph
Monograph Title Section Source Publication Page Number Errata Post Date Errata Official Date Target Errata Print Publication Target Online Fix Publication Description
QUETIAPINE TABLETS PERFORMANCE TESTS/Dissolution <711>/Test 3 USP38–NF33 5104 27-Mar-2015 1-Apr-2015 USP39–NF34 USP39–NF34 Line 7 of Instrumental conditions: Change
10 0mg,
to:
100 mg,
AND
Line 5 of Tolerances: Change
For Tablets labeled to contain 100 mg, 200 mg, 300 mg, or 400 mg:
to:
For Tablets labeled to contain 50 mg, 100 mg, 200 mg, 300 mg, or 400 mg:
PHENYTOIN SODIUM USP Reference standards <11> USP37–NF32 4289 27-Mar-2015 1-Apr-2015 USP39–NF34 USP39–NF34 Line 3 of USP Phenytoin Related Compound A RS: Change
C14H15NO2
to:
C14H13NO2
SORBITOL SORBITAN SOLUTION SPECIFIC TESTS USP37–NF32 6197 27-Mar-2015 1-Apr-2015 USP39–NF34 USP39–NF34 Line 1 of pH <791>: Change
4.0–7.0, in a 14% solution of Sorbitol Sorbitan Solution in carbon dioxide-free water
to:
4.0–7.0, in a 14% (w/w) solution of Sorbitol Sorbitan Solution in carbon dioxide-free water
MINERAL OIL SPECIFIC TESTS/Readily Carbonizable Substances Test <271> Second Supplement to USP37–NF32 Online 27-Mar-2015 1-Apr-2015 USP39–NF34 USP39–NF34 Line 1 of Acceptance criteria: Change
The Sample may turn hazy, but it remains colorless, or shows a slight pink or yellow color, and the Sample does not become darker than the Standard solution.
to:
The oil portion of the Sample may turn hazy, but it… Read More
COSYNTROPIN SPECIFIC TESTS/UV Absorption Spectrophotometry USP38–NF33 2958 27-Mar-2015 1-Apr-2015 USP39–NF34 USP39–NF34 Line 1 of Sample solution: Change
hydrochloride
to:
hydrochloric acid
AMINOBENZOIC ACID IMPURITIES/Organic Impurities USP37–NF32 1730 27-Mar-2015 1-Apr-2015 USP39–NF34 USP39–NF34 Add the subsection:
Standard stock solution: 0.25 mg/mL each of USP Benzocaine RS and 4-nitrobenzoic acid in methanol
AND
Line 2 of Standard solution: Change
in Mobile phase
to:
in Mobile phase, from the Standard stock solution
ASPARTAME ASSAY/Procedure USP37–NF32 5857 27-Mar-2015 1-Apr-2015 USP39–NF34 USP39–NF34 Line 3 of Analysis: Change
crystal violet
to:
crystal violet TS
RIVASTIGMINE TARTRATE ADDITIONAL REQUIREMENTS/USP Reference Standards <11> First Supplement to USP37–NF32 Online 27-Mar-2015 1-Apr-2015 USP39–NF34 USP39–NF34 Line 2 of USP Rivastigmine Related Compound A RS: Change
Di-p-toluoyl-D-(+)-tartaric acid monohydrate.
C20H20O9 404.37
to:
(+)-Di-(p-toluoyl)-D-tartaric acid.
C20H18O8 386.35
CLARITHROMYCIN TABLETS IMPURITIES/Organic Impurities/Chromatographic system USP38–NF33 2850 27-Mar-2015 1-Apr-2015 USP39–NF34 USP39–NF34 Line 1 of Column: Change
4.6-mm × 10-cm; 3-µm packing L1
to:
4.6-mm × 10-cm; 3.5-µm packing L1
RIVASTIGMINE TARTRATE CAPSULES ADDITIONAL REQUIREMENTS/USP Reference Standards <11> USP37–NF32 4616 27-Mar-2015 1-Apr-2015 USP39–NF34 USP39–NF34 Line 2 of USP Rivastigmine Related Compound A RS: Change
Di-p-toluoyl-D-(+)-tartaric acid monohydrate.
C20H20O9 404.37
to:
(+)-Di-(p-toluoyl)-D-tartaric acid.
C20H18O8 386.35
TREHALOSE IMPURITIES/Heavy Metals, Method I <231> USP37–NF32 6247 27-Mar-2015 1-Apr-2015 USP39–NF34 USP39–NF34 Line 1 of Monitor preparation: Change
Prepare with 2.5 mL of Standard Lead Solution.
to:
Prepare with 2.0 mL of Standard Lead Solution.
BISMUTH SUBCARBONATE IMPURITIES/Limit of Lead USP38–NF33 2449 27-Mar-2015 1-Apr-2015 USP39–NF34 USP39–NF34 Line 1 of Acceptance criteria: Change
Meets the requirements
to:
NMT 0.002%
QUETIAPINE FUMARATE IMPURITIES/Organic Impurities USP38–NF33 5102 27-Mar-2015 1-Apr-2015 USP39–NF34 USP39–NF34 Line 2 of Peak identification solution: Change
USP Quetiapine Fumarate Related Compound B RS
to:
USP Quetiapine Related Compound B RS
AND
Line 3 of Peak identification solution: Change
USP Quetiapine Fumarate Related Compound G RS
to:
USP Quetiapine Related… Read More
BETAMETHASONE DIPROPIONATE ASSAY/Procedure USP37–NF32 1961 27-Mar-2015 1-Apr-2015 USP39–NF34 USP39–NF34 Line 2 of Sample solution: Change
5.0 mL each of the Internal standard solution and the Standard stock solution
to:
5.0 mL each of the Internal standard solution and the Sample stock solution
PURIFIED BENTONITE IDENTIFICATION/A. X-Ray Diffraction <941> USP37–NF32 5862 27-Mar-2015 1-Apr-2015 USP39–NF34 USP39–NF34 Line 4 of Acceptance criteria: Change
from the pattern of Sample B is 1.492 and 1.504 Å.
to:
from the pattern of Sample B is between 1.492 and 1.504 Å.
RED CLOVER TABLETS SPECIFIC TESTS/Microbial Enumeration Tests <2021> USP37–NF32 5526 30-Jan-2015 1-Feb-2015 USP39–NF34 Second Supplement to USP38–NF33 Line 4: Change
NLT 103 cfu/g.
to:
NMT 103 cfu/g.
ATROPINE SULFATE ADDITIONAL REQUIREMENTS/USP Reference Standards <11> USP38–NF33 2325 30-Jan-2015 1-Feb-2015 USP39–NF34 Second Supplement to USP38–NF33 Line 2 of USP Hyoscyamine Related Compound A RS: Change
Norhyoscyamine sulfate; (1R,3r,5S)-8-azabicyclo [3.2.1]oct-3-yl(2S)-3-hydroxy-2-phenylpropanoate.C16H21NO3 275.34
to:
Norhyoscyamine sulfate; (1R,3r,5… Read More
CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE TABLETS ASSAY/Procedure USP38–NF33 2752 30-Jan-2015 1-Feb-2015 USP39–NF34 Second Supplement to USP38–NF33 Line 1 of Buffer: Change
0.20 sodium hydroxide
to:
0.20 N sodium hydroxide
PAROXETINE HYDROCHLORIDE ADDITIONAL REQUIREMENTS/USP Reference Standards <11> USP38–NF33 4765 30-Jan-2015 1-Feb-2015 USP39–NF34 Second Supplement to USP38–NF33 Lines 4 and 7 of USP Paroxetine System Suitability Mixture A RS: Change
hydrochloride (3 S-trans)
to:
hydrochloride (3S-trans)
GADOVERSETAMIDE INJECTION Relaxivity <761> USP37–NF32 3121 30-Jan-2015 1-Feb-2015 USP39–NF34 Second Supplement to USP38–NF33 Line 1 of Apparatus: Change
Use a mini-NMR spectrometer with suitable sensitivity (see Apparatus under Nuclear Magnetic Resonance <761>).
to:
Use an NMR spectrometer with suitable sensitivity.
BUPROPION HYDROCHLORIDE EXTENDED-RELEASE TABLETS IMPURITIES/Organic Impurities Revision Bulletin (Official October 01, 2014) Online 30-Jan-2015 1-Feb-2015 USP39–NF34 Second Supplement to USP38–NF33 Row 4 of Column 1 of Table 16: Change
R,S,S,-Thiomorpholine derivativec
to:
S,R,R,-Thiomorpholine derivativec
PANCURONIUM BROMIDE ASSAY/Procedure/Chromatographic system USP37–NF32 4176 30-Jan-2015 1-Feb-2015 USP39–NF34 Second Supplement to USP38–NF33 Line 1 of Column: Change
4.6-mm × 250-cm; 5-µm packing L1
to:
4.6-mm × 25-cm; 5-µm packing L1
VALSARTAN TABLETS PERFORMANCE TESTS/Dissolution <711> USP37–NF32 5116 30-Jan-2015 1-Feb-2015 USP39–NF34 Second Supplement to USP38–NF33 Line 1 of Medium: Change
pH 6.8 phosphate buffer; 1000 mL, degassed
to:
pH 6.8 phosphate buffer prepared as follows. Dissolve 6.805 g of monobasic potassium phosphate and 0.896 g of sodium hydroxide in and dilute with water to 1000 mL. Adjust with 0.2 M sodium hydroxide or 1 M… Read More
RISPERIDONE ADDITIONAL REQUIREMENTS/USP Reference Standards <11> Second Supplement to USP37–NF32 7240 30-Jan-2015 1-Feb-2015 USP39–NF34 Second Supplement to USP38–NF33 Line 2 of USP Risperidone Related Compound G RS: Change
3-[2-[4-(4-Fluoro-2-hydroxybenzoyl)piperidin-1-yl]ethyl]-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one.
C23H28FN3O3 413.49
to:
3-[2-[4-(4-… Read More
CAFFEINE CITRATE INJECTION ASSAY/Procedure USP38–NF33 2520 30-Jan-2015 1-Feb-2015 USP39–NF34 Second Supplement to USP38–NF33 Line 5 of Analysis: Change
Result = (rU/rS) × CS × (Mr1/Mr2) × 100
to:
Result = (rU/rS) × C… Read More
MESALAMINE RECTAL SUSPENSION OTHER COMPONENTS/Content of Sodium Benzoate (if present) USP38–NF33 4270 30-Jan-2015 1-Feb-2015 USP39–NF34 Second Supplement to USP38–NF33 Line 5 of Analysis: Change
Result = (rU/rS) × CS × (10/W) × 100
to:
Result = (rU/rS) × CS × (10/W)
CHLORAMPHENICOL SODIUM SUCCINATE Limit of free chloramphenicol USP37–NF32 2285 30-Jan-2015 1-Feb-2015 USP39–NF34 Second Supplement to USP38–NF33 Line 10 of Chromatographic system: Change
Chromatograph the Standard solution, and record the peak areas as directed for Procedure: the relative standard deviation for replicate injections is not less than 2.0%.
to:
Chromatograph the Standard solution, and… Read More
CIPROFLOXACIN EXTENDED-RELEASE TABLETS PERFORMANCE TESTS/Dissolution <711> Revision Bulletin (Official October 01, 2014) Online 30-Jan-2015 1-Feb-2015 USP39–NF34 Second Supplement to USP38–NF33 Line 13 of Analysis in Test 1: Change
Mr2 = molecular weight of ciprofloxacin hydrochloride, 367.81
to:
Mr2 = molecular weight of anhydrous ciprofloxacin hydrochloride, 367.81
AND
Line 12 of Analysis in Test… Read More
METHOTREXATE IMPURITIES/Organic Impurities/Procedure 1: Related Compounds USP37–NF32 3762 30-Jan-2015 1-Feb-2015 USP39–NF34 Second Supplement to USP38–NF33 Line 1 of Standard solution A: Change
0.1 μg/mL of USP Methotrexate RS in Solution A, from the Standard stock solution
to:
0.1 µg/mL of USP Methotrexate RS in Solution A, from Standard stock solution A
TERAZOSIN TABLETS PERFORMANCE TESTS/Dissolution <711> USP37–NF32 4874 30-Jan-2015 1-Feb-2015 USP39–NF34 Second Supplement to USP38–NF33 Line 10 of Analysis: Change
Mr2 = molecular weight of terazosin hydrochloride dihydrate, 459.92
to:
Mr2 = molecular weight of terazosin hydrochloride, 423.89
EXTENDED PHENYTOIN SODIUM CAPSULES IDENTIFICATION/A. Infrared Absorption—General <197> First Supplement to USP37–NF32 6681 30-Jan-2015 1-Feb-2015 USP39–NF34 Second Supplement to USP38–NF33 Line 1 of Sample: Change
6 mg/mL of phenytoin sodium in water from a suitable number of Capsules prepared as follows. Nominally transfer 300 mg of the powder into 50 mL of water in a separator.
to:
300 mg of phenytoin sodium from the contents of Capsules in 50 mL of water in a… Read More
BUTABARBITAL SODIUM ORAL SOLUTION ASSAY/Procedure USP38–NF33 2500 30-Jan-2015 1-Feb-2015 USP39–NF34 Second Supplement to USP38–NF33 Line 17 of Analysis: Change
CU = nominal concentration of butabarbital sodium in the Sample solution (µg/mL)
to:
CU = nominal concentration of butabarbital sodium in the Sample solution (mg/mL)
CITRIC ACID, MAGNESIUM OXIDE, AND SODIUM CARBONATE IRRIGATION ASSAY/Citric Acid USP38–NF33 2844 30-Jan-2015 1-Feb-2015 USP39–NF34 Second Supplement to USP38–NF33 Line 16 of Analysis: Change
CU = nominal concentration of citric acid monohydrate in the Assay preparation for citric acid/citrate assay (units/mL)
to:
CU = nominal concentration of citric acid monohydrate in the Assay… Read More
AZITHROMYCIN IMPURITIES/Organic Impurities/Procedure 1 USP37–NF32 1886 30-Jan-2015 1-Feb-2015 USP39–NF34 Second Supplement to USP38–NF33 Line 6 of Analysis: Change
Calculate the percentages of desosaminylazithromycin and N-demethylazithromycin in the portion of Azithromycin taken:
to:
Calculate the percentages of desosaminylazithromycin, N-demethylazithromycin, and azaerythromycin A in the portion of… Read More
VALSARTAN AND HYDROCHLOROTHIAZIDE TABLETS ADDITIONAL REQUIREMENTS/USP Reference Standards <11> Revision Bulletin (Official April 01, 2014) Online 30-Jan-2015 1-Feb-2015 USP39–NF34 Second Supplement to USP38–NF33 Line 2 of USP Valsartan Related Compound B RS: Change
(S-N-Butyryl-N-([2′-(1H-tetrazole-5-yl)biphen-4-yl]methyl)-valine.
to:
N-Butyryl-N-{[2′-(1H-tetrazole-5-yl)biphenyl-4-yl]methyl}-L-valine.
HYDROGEN PEROXIDE CONCENTRATE ASSAY/Procedure USP37–NF32 3272 30-Jan-2015 1-Feb-2015 USP39–NF34 Second Supplement to USP38–NF33 Line 1 of Sample solution: Change
1 mL of Concentrate, diluted to 100 mL
to:
Weigh about 1 mL of Concentrate in a 100-mL volumetric flask, and dilute with water to volume.
POTASSIUM BITARTRATE IDENTIFICATION USP37–NF32 4346 30-Jan-2015 1-Feb-2015 USP39–NF34 Second Supplement to USP38–NF33 Change
C. Identification Tests—General, Tartrate <191>
to:
C. Identification Tests—General, Tartrate <191>: Meets the requirements
AND
Delete subsections:
Sample solution: 1 in 10 solution
Acceptance criteria: Meets the requirements
ZIPRASIDONE HYDROCHLORIDE IMPURITIES/Limit of Tetrahydrofuran USP37–NF32 5219 30-Jan-2015 1-Feb-2015 USP39–NF34 Second Supplement to USP38–NF33 Line 1 of Standard solution: Change
0.05 mg/mL of USP Ziprasidone Hydrochloride RS in dimethyl sulfoxide
to:
0.05 mg/mL of tetrahydrofuran in dimethyl sulfoxide
AMIODARONE HYDROCHLORIDE ORGANIC IMPURITIES/Procedure 1/Chromatographic system USP38–NF33 2198 30-Jan-2015 1-Feb-2015 USP39–NF34 Second Supplement to USP38–NF33 Line 1 of Adsorbent: Change
0.5-mm layer of chromatographic silica gel and fluorescent indicator with maximum absorbance at 254 nm
to:
Suitable layer of chromatographic silica gel and fluorescent indicator with maximum absorbance at 254 nm
CAFFEINE CITRATE ORAL SOLUTION ASSAY/Procedure USP38–NF33 2521 30-Jan-2015 1-Feb-2015 USP39–NF34 Second Supplement to USP38–NF33 Line 5 of Analysis: Change
Result = (rU/rS) × CS × (Mr1/Mr2) × 100
to:
Result = (rU/rS) × C… Read More
PAROXETINE HYDROCHLORIDE IMPURITIES/Limit of 1-Methyl-4-(p-fluorophenyl)-1,2,3,6-tetrahydropyridine USP38–NF33 4765 30-Jan-2015 1-Feb-2015 USP39–NF34 Second Supplement to USP38–NF33 Line 1 of Standard solution: Change
42 mg/mL
to:
42 ng/mL
ESTRADIOL VAGINAL INSERTS PERFORMANCE TESTS/Dissolution <711> USP37–NF32 2866 30-Jan-2015 1-Feb-2015 USP39–NF34 Second Supplement to USP38–NF33 Line 3 of Analysis: Change
Calculate the amount of estradiol (C18H24O2) dissolved:
to:
Record the chromatograms, and measure the responses for the estradiol peak. Construct a calibration curve by plotting the peak response versus concentration of… Read More
CIPROFLOXACIN EXTENDED-RELEASE TABLETS IMPURITIES/Organic Impurities Revision Bulletin (Official October 01, 2014) Online 30-Jan-2015 1-Feb-2015 USP39–NF34 Second Supplement to USP38–NF33 Line 16 of Analysis: Change
Mr2 = molecular weight of ciprofloxacin hydrochloride, 367.81
to:
Mr2 = molecular weight of anhydrous ciprofloxacin hydrochloride, 367.81
AND
Line 14 of the second Calculate statement in Analysis… Read More
PACLITAXEL Related compounds/Test 2 (for Material Labeled as Produced by a Semisynthetic Process) USP37–NF32 4163 30-Jan-2015 1-Feb-2015 USP39–NF34 Second Supplement to USP38–NF33 Line 6 after table in Chromatographic system: Change
the relative standard deviation for replicate injections is not more than 2.0%.
to:
the relative standard deviation for replicate injections is not more than 2.0% for the paclitaxel peak.
TETRACAINE OINTMENT Assay USP37–NF32 4891 30-Jan-2015 1-Feb-2015 USP39–NF34 Second Supplement to USP38–NF33 Line 7 of Procedure: Change
(264.37/300.83)(C)(AU / AS)
to:
(264.36/300.82)(C)(AU / AS)
GLYCERYL BEHENATE ASSAY/Procedure/Chromatographic system Second Supplement to USP37–NF32 7075 30-Jan-2015 1-Feb-2015 USP39–NF34 Second Supplement to USP38–NF33 Line 1 of Column: Change
7.0-mm × 60-cm; 5-µm packing L21
[Note—Two 7.0-mm × 30-cm L21 columns
to:
7.5-mm × 60-cm; 5-µm 100-Å packing L21
[Note—Two 7.5-mm × 30-cm L21 columns
BUTABARBITAL SODIUM TABLETS PERFORMANCE TESTS/Uniformity of Dosage Units <905>/Procedure for content uniformity USP38–NF33 2501 30-Jan-2015 1-Feb-2015 USP39–NF34 Second Supplement to USP38–NF33 Line 18 of Analysis: Change
CU = nominal concentration of butabarbital sodium in the Sample solution
to:
CU = nominal concentration of butabarbital sodium in the Sample solution (mg/mL)
ESCITALOPRAM TABLETS PERFORMANCE TESTS/Dissolution <711>/Test 2 USP38–NF33 3364 30-Jan-2015 1-Feb-2015 USP39–NF34 Second Supplement to USP38–NF33 Line 13 of Analysis: Change
Mr2 = molecular weight of escitalopram oxalate, 405.30
to:
Mr2 = molecular weight of escitalopram oxalate, 414.43
AZITHROMYCIN SPECIFIC TESTS/pH <791> USP37–NF32 1886 30-Jan-2015 1-Feb-2015 USP39–NF34 Second Supplement to USP38–NF33 Line 1 of Sample solution: Change
2 mg/mL from the Sample stock solution in a mixture of methanol and water (1:1)
to:
2 mg/mL obtained by mixing equal volumes of Sample stock solution and water
CIPROFLOXACIN EXTENDED-RELEASE TABLETS ASSAY/Procedure Revision Bulletin (Official October 01, 2014) Online 30-Jan-2015 1-Feb-2015 USP39–NF34 Second Supplement to USP38–NF33 Line 17 of Analysis: Change
Mr2 = molecular weight of ciprofloxacin hydrochloride, 367.81
to:
Mr2 = molecular weight of anhydrous ciprofloxacin hydrochloride, 367.81